Restasis Buyers Seek $16M Atty Fees In Antitrust Case
A class of buyers that reached a $51 million settlement with Allergan over allegations that it illegally kept generic rivals to its dry eye treatment Restasis off the shelves has asked a New York federal...To view the full article, register now.
Already a subscriber? Click here to view full article